Updated:
SignPath Pharma, Inc.
SignPath Pharma, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001455694, and its reported industry...
Overview
SignPath Pharma, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001455694, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2016-04-08, it reported net income of USD -1,634,990; total assets of USD 697,933 for the fiscal period ended 2015-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.
Company overview
- Legal name
- SignPath Pharma, Inc.
- Classification
- Company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- Sandy, UT, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001455694
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Net income | Total assets | Operating cash flow |
|---|---|---|---|---|
| FY2015USD | -$1.6M | $697,933 | -$1.5M | |
| FY2014USD | -$2.7M | $716,193 | -$2.2M | |
| FY2013USD | -$2.0M | $1.2M | -$1.6M | |
| FY2012USD | -$1.3M | $32,066 | -$883,328 |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 10-Q | Form 10-Q | ||
| 10-Q | Form 10-Q | ||
| 10-K | Form 10-K | ||
| 10-Q | Form 10-Q | ||
| 8-K | FORM 8-K | ||
| 10-Q | Form 10-Q | ||
| 10-Q | SIGNPATH PHARMA INC.10Q 2015-03-31 | ||
| 8-K | SIGNPATH PHARMA INC. 8K 2015-05-01 | ||
| 10-K | SIGHPATH PHARMA 10K 2014-12-31 | ||
| 8-K | FORM 8-K | ||
| 8-K | SIGNPATH PHARMA INC. 8K 201501-27 | ||
| 10-Q | SIGNPATH PHARMA INC. 10Q 2014-09-30 |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research SignPath Pharma, Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.